NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No 278 - Omalizumab for the treatment of severe persistent allergic asthma

**Matrix of consultees and commentators**

|  |  |
| --- | --- |
| **Consultees** | **Commentators (no right to submit or appeal)** |
| Company/sponsor* Novartis (omalizumab)

Patient/carer groups* Action Against Allergy
* Action for Sick Children
* Allergy UK
* Anaphylaxis Campaign
* Asthma UK
* Black Health Agency
* British Lung Foundation
* European Federation of Allergy and Airways Diseases Patients Associations Muslim Council of Britain
* National Children's Bureau
* South Asian Health Foundation
* Specialised Healthcare Alliance

Professional groups* Association of Respiratory Nurse Specialists
* British Geriatrics Society
* British Paediatric Respiratory Society
* British Society for Allergy and Clinical Immunology
* British Thoracic Society
* Primary Care Respiratory Society UK
* Royal College of General Practitioners
* Royal College of Nursing
* Royal College of Paediatrics & Child Health
* Royal College of Pathologists
* Royal College of Physicians
* Royal Pharmaceutical Society
* Royal Society of Medicine
* UK Clinical Pharmacy Association

Others* Department of Health
* NHS England
* NHS Leeds North CCG
* NHS Vale Royal CCG
* Welsh Government
 | General commentators* Allied Health Professionals Federation
* Association of British Healthcare Industries
* Board of Community Health Councils in Wales
* British National Formulary
* Care Quality Commission
* Department of Health, Social Services and Public Safety for Northern Ireland
* Healthcare Improvement Scotland
* Medicines and Healthcare Products Regulatory Agency
* National Association of Primary Care
* National Pharmacy Association
* NHS Alliance
* NHS Commercial Medicines Unit
* NHS Confederation
* Scottish Medicines Consortium

Comparators* None

Relevant research groups* Asthma, Allergy and Inflammation Research Trust
* British Association for Lung Research
* Cochrane Airways Group
* David Hide Asthma and Allergy Research Centre
* MRC Clinical Trials Unit
* National Institute for Health Research
* National Society for Research into Allergy
* Research Institute for the Care of Older People

Associated Public Health Groups* Public Health England
* Public Health Wales
 |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal

Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.